Cibc Asset Management Inc Denali Therapeutics Inc. Transaction History

Cibc Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$29.0 - $47.27 $147,001 - $239,611	-5,069 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$42.59 - $55.02 $7,921 - $10,233	186 Added 3.81%	5,069 $226,000
Q3 2021 Nov 09, 2021	BUY	$48.48 - $78.23 $21,573 - $34,812	445 Added 10.03%	4,883 $246,000
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $44,492 - $67,425	827 Added 22.9%	4,438 $253,000
Q4 2020 Feb 03, 2021	BUY	$36.89 - $93.56 $133,209 - $337,845	3,611 New	3,611 $302,000

239

111M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $1.98B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.